Cytodyn INC 10-K annual reports

CytoDyn Inc. announced a net income of $3.7 million for fiscal year 2025, primarily due to a $25.0 million legal settlement, as it refocuses its clinical development on solid-tumor oncology while facing significant liquidity challenges and ongoing regulatory investigations.

CytoDyn Inc. has filed an amendment to its annual report to include previously omitted information and correct an exhibit, with no changes to previously reported financial results.

CytoDyn Inc.'s annual 10-K filing details a strategic pivot towards oncology and inflammation research, alongside the development of a long-acting version of their drug, leronlimab.